Supplementary Fig. 4a shows another patient with an increase in the DP CD8+ TIL subset after anti-OX40 treatment and a patient with low expression of this subset in the tumor, which remained unchanged after anti-OX40 treatment (Supplementary Fig. 4b, c). This evidence concerns the gene TNFRSF4 and neoplasm.